MedPath

Inspiratory Muscle Strength Training in Adults With Type 2 Diabetes

Not Applicable
Completed
Conditions
Hypertension
Diabetes Mellitus, Type 2
Interventions
Behavioral: Inspiratory muscle strength training (IMST)
Registration Number
NCT05643768
Lead Sponsor
University of Arizona
Brief Summary

This clinical research study will investigate the effects of 6 weeks of inspiratory muscle strength training on metabolic and cardiovascular outcomes in adults with recent-onset type 2 diabetes.

Detailed Description

Type 2 diabetes mellitus (T2DM) is at epidemic proportions in the United States and worldwide. It is a chronic obesity-associated metabolic disorder characterized by glucose dysregulation combined with insulin resistance and beta-cell defects. First-line T2DM treatments include lifestyle remedies, such as dietary modifications and exercise. Exercise, whether aerobic and/or resistance training, increases whole-body insulin sensitivity and stimulates muscle glucose uptake independent of insulin. The acute effects of exercise on muscle in patients with abnormal glucose regulation produce immediate improvements in blood glucose levels. In addition, when exercise is repeated over time, adaptations occur that include more long-lasting increases in insulin sensitivity. The effects of traditional exercise on glycemic control and insulin sensitivity in patients with T2DM are well established. However, adherence to traditional exercise programs is low, in part, due to lack of time and physical discomfort, and new regimens for T2DM treatment are needed.

Recently, a novel time-efficient respiratory exercise called Inspiratory Muscle Strength Training (IMST) was developed. IMST is distinct from other traditional forms of exercise as it is only 5 minutes per session and performed on a hand-held device during stationary sitting or standing. Typically, IMST comprises 5 sets of 6 inspiratory maneuvers with 1-minute rests between sets. Previous studies demonstrate that 6 weeks of IMST improve systolic blood pressure (SBP), sympathetic nervous system activity, and endothelial function in healthy individuals, middle-aged and older people, and adults with obstructive sleep apnea. These BP-lowering effects of IMST are significant for reducing the risks of cardiovascular disease (CVD), the number one cause of death in people living with diabetes. IMST is safe and tolerable, with adherence rates \>90% in diverse populations, and presents a manageable program for improving metabolic health in T2DM patients who have difficulty maintaining a traditional exercise program requiring a large amount of time and physical exertion. It is unknown if IMST, a highly-abbreviated respiratory exercise that is not physically demanding, has beneficial effects on glycemic control and insulin sensitivity, in combination with its improvements on BP measures, in patients with T2DM. The potential for IMST to exert metabolic benefits in diabetic patients warrants assessment

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • diagnosed with type 2 diabetes by physician
  • fasting plasma glucose levels ≥126 mg/dl and ≤240 mg/dl
  • systolic blood pressure between 120-169 mmHg
  • stable dose of medication (three months on the same dose)
  • weight stable in the prior 3 months (<3.0 kg weight change) and willing to remain weight stable throughout the study
  • absence of unstable clinical disease as determined by medical history
Exclusion Criteria
  • current smoker (including tobacco products, vaping devices, THC, etc...)
  • have an uncontrolled medical condition (e.g., cancer)
  • myocardial infarction or stroke within the previous 12 months
  • performs regular aerobic exercise (>4 bouts/week)
  • BMI ≥ 40 kg/m2
  • systolic blood pressure <120 or ≥170 mmHg
  • diastolic blood pressure >100 or <60 mmHg
  • Cheyne-Stokes respiration
  • history of perforated eardrum
  • history of glaucoma or retinopathy
  • history of collapsed lung
  • diagnosed with asthma
  • pregnant, breastfeeding, or trying to become pregnant (self-reported)
  • medications that, in the opinion of the study physician or nurse practitioner, may impact the outcomes of the study (e.g., steroids)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High-resistance IMSTInspiratory muscle strength training (IMST)30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, 6 weeks
Low-resistance IMSTInspiratory muscle strength training (IMST)30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, 6 weeks
Primary Outcome Measures
NameTimeMethod
Change from baseline fasting blood plasma glucose after 6 weeks of IMSTBlood plasma collected and analyzed at baseline and after 6 weeks of training

A blood sample will be collected after 12 hours of fasting. Blood and plasma will be separated and plasma glucose levels will be quantified.

Change from baseline insulin sensitivity after 6 weeks of IMSTBlood plasma collected and analyzed at baseline and after 6 weeks of training

A blood sample will be collected after 12 hours of fasting. Insulin sensitivity will be calculated using the homeostatic model assessment of insulin resistance (HOMA-IR): (fasting serum insulin (mU/L) × fasting plasma glucose (mmol/L) × 22.5).

Change from baseline fasting blood plasma Insulin after 6 weeks of IMSTBlood plasma collected and analyzed at baseline and after 6 weeks of training

A blood sample will be collected after 12 hours of fasting. Blood and plasma will be separated and plasma insulin levels will be quantified.

Secondary Outcome Measures
NameTimeMethod
Change from baseline systolic blood pressure after 6 weeks of IMSTBlood pressure will be assessed at baseline and after 6 weeks of training

Change in systolic blood pressure (SBP) will be measured by both relative and absolute changes from baseline. SBP will be assessed in accordance with American College of Cardiology/American Heart Association guidelines. Measurements will be taken using an automated oscillometric sphygmomanometer and will be performed in triplicate over the brachial artery of the left arm after 5 minutes of quiet rest, with 1 minute of recovery between measures. SBP will be defined as the average of the 3 pressures.

Change from baseline Nitric Oxide-mediated Endothelial Dependent Dilation (EDD)EDD will be assessed at baseline and after 6 weeks of training

Brachial artery Flow Mediated Dilation (BA-FMD), a well-established measure of NO-mediated endothelial function, will be measured by both relative and absolute changes from baseline. BA-FMD will be determined using high-resolution ultrasonography and analyzed with a commercially available software package. An ultrasound probe will be placed 3-6 cm proximal to the antecubital crease on the right arm and a baseline image of the right brachial artery will be obtained. Following baseline, reactive hyperemia will be produced by inflating a rapid-inflating blood pressure cuff. Brachial artery diameter change will be measured for 2 minutes following 5-min of forearm blood flow occlusion.

Trial Locations

Locations (1)

Arizona Respiratory and Neurophysiology Laboratory

🇺🇸

Tucson, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath